Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer
利用胰腺癌中 STING 激活引起的脆弱性
基本信息
- 批准号:10549375
- 负责人:
- 金额:$ 56.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-15 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:ATR geneAgonistAnabolismBiochemical ProcessCancer EtiologyCell LineCell ReprogrammingCellsCellular Metabolic ProcessClinicalClinical TrialsCombined Modality TherapyConsumptionDNA RepairDNA Replication InductionDNA biosynthesisDataData AnalysesDeoxyribonucleosidesDeoxyribonucleotidesDependenceDiseaseEndotheliumEnzymesFamilyFutureGene ActivationGeneticGenetic ModelsGenetic TranscriptionGoalsImmuneImmunocompetentImpairmentIn VitroInflammatoryInterferon Type IInterferonsInvestigationKnowledgeLinkMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMass Spectrum AnalysisMediatingMetabolicMetabolismNADPNiacinamideNicotinamide adenine dinucleotideNon-MalignantNucleotidesPARP9 genePancreatic Ductal AdenocarcinomaPathway interactionsPhosphoric Monoester HydrolasesPoly(ADP-ribose) PolymerasesProcessProductionPropertyProteinsProteomicsRecyclingResistanceRoleSAM DomainSignal InductionSignal PathwaySignal TransductionSolid NeoplasmSourceStimulator of Interferon GenesStress Response SignalingTestingTherapeuticTherapeutic EffectUp-Regulationanti-PD-1anticancer treatmentantitumor effectbiological adaptation to stresscancer cellcancer therapycell growthclinical translationcofactorcytokinedesignimmune checkpoint blockadeimmunoregulationimplantationimprovedin vivoin vivo Modelinhibitormembermetabolomicsmortalitymouse modelneoplastic cellnicotinamide phosphoribosyltransferasenovelnovel therapeutic interventionnovel therapeuticsnucleotide metabolismoverexpressionpancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelpatient derived xenograft modelphosphoproteomicspreventrational designreplication stressrepositorysensorsynergismtherapy designtripolyphosphatetumortumor growthtumor microenvironment
项目摘要
PROJECT SUMMARY/ABSTRACT
Stimulator of interferon genes (STING) is an emerging target for the treatment of solid tumors. Investigations of
the therapeutic relevance of STING agonists have primarily focused on the immunomodulatory effects
mediated by STING-activation dependent induction of type I interferons (IFN) in the tumor microenvironment.
However, how IFN signaling induced by STING agonists impacts malignant cell signaling and metabolism is
poorly understood and, whether these effects can be therapeutically exploited has not been investigated. Data
are presented showing that STING is highly over-expressed in pancreatic ductal adenocarcinoma (PDAC) and
that its activation in PDAC malignant cells results in impaired tumor growth in an IFN-signaling dependent
manner. Thus, elucidating the consequences of STING-driven IFN signaling is particularly relevant in PDAC
which is the third-leading cause of cancer-related mortality in the U.S. with an overall survival of less than one
year. Preliminary metabolomic and proteomic analyses point to two major interconnected biochemical
processes impacted by IFN signaling in PDAC cells: (i) nucleotide metabolism, which is evidenced by the
depletion of deoxyribonucleotide triphosphate (dNTP) and nicotinamide adenine dinucleotide (NAD) pools; and
(ii) activation of the DNA replication stress response signaling pathway mediated by Ataxia Telangiectasia and
Rad3-related protein (ATR). This proposal is designed to test the hypothesis that STING-driven dNTP and
NAD depletion in malignant cells result from the transcriptional upregulation of SAM domain and HD domain-
containing protein 1 (SAMHD1), a powerful dNTP phosphohydrolase, and of specific members of the poly-
ADP-ribose-polymerase (PARP) family (PARP9/10/14) which increase NAD consumption, respectively. It will
further test the hypothesis that malignant cells engage specific adaptive mechanisms to counteract these
metabolic alterations and that their inhibition will synergize with STING agonists. Studies in Aim 1 will
investigate the consequences of STING activation in orthotopic PDAC cell line and patient-derived xenograft
models from a pre-existing repository and will investigate mechanistic links between STING activation and
replication stress. Studies in Aim 2 will test rationally designed combination therapies that block two major co-
dependencies elicited by STING activation in PDAC cells: (i) the ATR-regulated replication stress response
and (ii) nicotinamide phosphoribosyltransferase (NAMPT)-mediated nicotinamide recycling. Studies in Aim 3
will employ immunocompetent implantation and autochthonous PDAC models to test the concept of targeting
co-dependencies identified in Aims 1 and 2 in the context provided by ongoing clinical trials in which STING
agonists are combined with immune checkpoint blockade. Collectively, studies proposed in this application are
designed to increase the understanding of the interplay between STING signaling, nucleotide/NAD metabolism
and replication stress response in PDAC with the ultimate goal of uncovering critical vulnerabilities to be
exploited by new therapeutic approaches against this extremely aggressive and difficult to treat malignancy.
项目概要/摘要
干扰素基因刺激物(STING)是治疗实体瘤的新兴靶点。调查
STING 激动剂的治疗相关性主要集中在免疫调节作用
由肿瘤微环境中 I 型干扰素 (IFN) 的 STING 激活依赖性诱导介导。
然而,STING 激动剂诱导的 IFN 信号传导如何影响恶性细胞信号传导和代谢尚不清楚。
人们对此知之甚少,并且尚未研究这些效应是否可以用于治疗。数据
表明 STING 在胰腺导管腺癌 (PDAC) 中高度过表达,并且
它在 PDAC 恶性细胞中的激活会导致 IFN 信号依赖性肿瘤生长受损
方式。因此,阐明 STING 驱动的 IFN 信号传导的后果在 PDAC 中尤其重要
这是美国癌症相关死亡的第三大原因,总体生存率不到一
年。初步代谢组学和蛋白质组学分析指出两个主要的相互关联的生物化学
PDAC 细胞中受 IFN 信号传导影响的过程:(i) 核苷酸代谢,这由
脱氧核糖核苷酸三磷酸 (dNTP) 和烟酰胺腺嘌呤二核苷酸 (NAD) 池的耗尽;和
(ii) 共济失调毛细血管扩张介导的 DNA 复制应激反应信号通路的激活和
Rad3 相关蛋白 (ATR)。该提案旨在测试 STING 驱动的 dNTP 和
恶性细胞中 NAD 的消耗是由于 SAM 结构域和 HD 结构域的转录上调造成的
含有蛋白质 1 (SAMHD1),一种强大的 dNTP 磷酸水解酶,以及多聚体的特定成员
ADP-核糖聚合酶 (PARP) 家族 (PARP9/10/14) 分别增加 NAD 消耗。它会
进一步检验恶性细胞利用特定的适应性机制来抵消这些的假设
代谢改变及其抑制作用将与 STING 激动剂产生协同作用。目标 1 的研究将
研究原位 PDAC 细胞系和患者来源的异种移植物中 STING 激活的后果
来自预先存在的存储库的模型,并将研究 STING 激活和
复制压力。目标 2 的研究将测试合理设计的联合疗法,以阻断两种主要的联合疗法:
PDAC 细胞中 STING 激活引起的依赖性:(i) ATR 调节的复制应激反应
(ii) 烟酰胺磷酸核糖转移酶 (NAMPT) 介导的烟酰胺回收。目标 3 的研究
将采用免疫活性植入和本地 PDAC 模型来测试靶向概念
在正在进行的临床试验提供的背景下,目标 1 和 2 中确定了相互依赖性,其中 STING
激动剂与免疫检查点阻断相结合。总的来说,本申请中提出的研究是
旨在加深对 STING 信号传导、核苷酸/NAD 代谢之间相互作用的理解
PDAC 中的复制压力响应,最终目标是发现关键漏洞
利用新的治疗方法来对抗这种极具侵袭性且难以治疗的恶性肿瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Timothy R Donahue其他文献
Timothy R Donahue的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Timothy R Donahue', 18)}}的其他基金
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer
利用胰腺癌中 STING 激活引起的脆弱性
- 批准号:
10350646 - 财政年份:2021
- 资助金额:
$ 56.54万 - 项目类别:
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer
利用胰腺癌中 STING 激活引起的脆弱性
- 批准号:
10737773 - 财政年份:2021
- 资助金额:
$ 56.54万 - 项目类别:
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer
利用胰腺癌中 STING 激活引起的脆弱性
- 批准号:
10533556 - 财政年份:2021
- 资助金额:
$ 56.54万 - 项目类别:
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer
靶向 KRAS 和腺苷介导的胰腺癌免疫抑制
- 批准号:
10583537 - 财政年份:2021
- 资助金额:
$ 56.54万 - 项目类别:
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer
靶向 KRAS 和腺苷介导的胰腺癌免疫抑制
- 批准号:
10224563 - 财政年份:2021
- 资助金额:
$ 56.54万 - 项目类别:
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer
靶向 KRAS 和腺苷介导的胰腺癌免疫抑制
- 批准号:
10358617 - 财政年份:2021
- 资助金额:
$ 56.54万 - 项目类别:
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer
加州大学洛杉矶分校多功能介孔二氧化硅纳米颗粒平台用于治疗胰腺癌
- 批准号:
9150536 - 财政年份:2015
- 资助金额:
$ 56.54万 - 项目类别:
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer
加州大学洛杉矶分校多功能介孔二氧化硅纳米颗粒平台用于治疗胰腺癌
- 批准号:
9335325 - 财政年份:2015
- 资助金额:
$ 56.54万 - 项目类别:
UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of Pancreas Cancer
加州大学洛杉矶分校多功能介孔二氧化硅纳米颗粒平台用于治疗胰腺癌
- 批准号:
8959561 - 财政年份:2015
- 资助金额:
$ 56.54万 - 项目类别:
相似国自然基金
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
TLR7激动剂活化MEG3/miR-185-5p/FABP4通路调节骨肉瘤巨噬细胞脂代谢促进M1极化的机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Pex11a激动剂酪酸激活过氧化物酶体增殖与代谢治疗糖尿病肾病的分子机制
- 批准号:82070834
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
基于多样性激动剂的PPARβ/δ调节脂骨代谢作用与机制及药物先导物发现研究
- 批准号:
- 批准年份:2019
- 资助金额:54 万元
- 项目类别:面上项目
GLP-1受体激动剂通过IRS-1/PI3K/Akt信号通路调节骨代谢
- 批准号:81860163
- 批准年份:2018
- 资助金额:35.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
- 批准号:
10752555 - 财政年份:2024
- 资助金额:
$ 56.54万 - 项目类别:
The role of osteoblast progenitors in response to bone anabolic agents
成骨细胞祖细胞对骨合成代谢剂的反应的作用
- 批准号:
10404415 - 财政年份:2023
- 资助金额:
$ 56.54万 - 项目类别:
Center of Research Translation on Osteoporosis Bone Anabolic Therapies
骨质疏松症骨合成代谢疗法研究转化中心
- 批准号:
10404412 - 财政年份:2023
- 资助金额:
$ 56.54万 - 项目类别:
Alcohol-induced epigenetic reprogramming of PPAR-α affects allopregnanolone biosynthesis
酒精诱导的 PPAR-α 表观遗传重编程影响异孕酮生物合成
- 批准号:
10658534 - 财政年份:2023
- 资助金额:
$ 56.54万 - 项目类别:
Control of insulin secretion by mitochondrial fusion
通过线粒体融合控制胰岛素分泌
- 批准号:
10753730 - 财政年份:2023
- 资助金额:
$ 56.54万 - 项目类别: